Charan Singh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3175939/publications.pdf Version: 2024-02-01



CHADAN SINCH

#	Article	IF	CITATIONS
1	Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability. Carbohydrate Polymers, 2016, 137, 339-349.	10.2	109
2	Development of tamoxifen-phospholipid complex: Novel approach for improving solubility and bioavailability. International Journal of Pharmaceutics, 2014, 473, 1-9.	5.2	92
3	Novel rifampicin–phospholipid complex for tubercular therapy: Synthesis, physicochemical characterization and in-vivo evaluation. International Journal of Pharmaceutics, 2014, 460, 220-227.	5.2	82
4	Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico , in vitro and in vivo evaluation. Carbohydrate Polymers, 2015, 134, 547-556.	10.2	79
5	Folic acid functionalized long-circulating co-encapsulated docetaxel and curcumin solid lipid nanoparticles: <i>In vitro</i> evaluation, pharmacokinetic and biodistribution in rats. Drug Delivery, 2016, 23, 1453-1468.	5.7	64
6	Potential of aerosolized rifampicin lipospheres for modulation of pulmonary pharmacokinetics and bio-distribution. International Journal of Pharmaceutics, 2015, 495, 627-632.	5.2	28
7	Novel potential for optimization of antitubercular therapy: Pulmonary delivery of rifampicin lipospheres. Asian Journal of Pharmaceutical Sciences, 2015, 10, 549-562.	9.1	17
8	In Vitro-In Vivo Evaluation of Novel Co-spray Dried Rifampicin Phospholipid Lipospheres for Oral Delivery. AAPS PharmSciTech, 2017, 18, 138-146.	3.3	17
9	Inhalation potential of N-Acetylcysteine loaded PLGA nanoparticles for the management of tuberculosis: In vitro lung deposition and efficacy studies. Current Research in Pharmacology and Drug Discovery, 2022, 3, 100084.	3.6	15
10	A review on recent advances in nanomedicines for the treatment of pulmonary tuberculosis. Journal of Drug Delivery Science and Technology, 2022, 69, 103069.	3.0	12
11	Inhalational Drug Delivery in Pulmonary Aspergillosis. Critical Reviews in Therapeutic Drug Carrier Systems, 2019, 36, 183-217.	2.2	10
12	Topical application of nanoparticles integrated supramolecular hydrogels for the potential treatment of seborrhoeic dermatitis. Pharmaceutical Development and Technology, 2020, 25, 748-756.	2.4	10
13	Hepatoprotective agent tethered isoniazid for the treatment of drug-induced hepatotoxicity: Synthesis, biochemical and histopathological evaluation. Toxicology Reports, 2014, 1, 885-893.	3.3	9
14	Development of Novel Polymer-Lipid Hybrid Nanoparticles of Tamoxifen: <i>In Vitro</i> and <i>In Vivo</i> Evaluation. Journal of Nanoscience and Nanotechnology, 2016, 16, 253-260.	0.9	9
15	Attenuation potential of rifampicin–phospholipid complex in murine hepatotoxicity model. Journal of Drug Delivery Science and Technology, 2015, 30, 225-231.	3.0	7
16	Inhalation Potential of Rifampicin-Loaded Novel Metal–Organic Frameworks for Improved Lung Delivery: Physicochemical Characterization, <i>In Vitro</i> Aerosolization and Antimycobacterial Studies. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2022, 35, 259-268.	1.4	6
17	Novel metal organic frameworks improves solubility and oral absorption of mebendazole: Physicochemical characterization and in vitro-in vivo evaluation. Journal of Drug Delivery Science and Technology, 2022, 70, 103264.	3.0	2